Table 1.

NAT2 allele distribution among controls from case-control studies of breast, prostate, and stomach cancers

AlleleNucleotide substitution(s)Breast, n = 387 [n Alleles (%)]Stomach, n = 414 [n Alleles (%)]Prostate, n = 149 [n Alleles (%)]
NAT2*4None187 (24.2)219 (26.4)64 (21.5)
NAT2*5AT341C, C481T20 (2.6)7 (0.85)5 (1.7)
NAT2*5BT341C, C481T, A803G318 (41.1)309 (37.3)104 (34.9)
NAT2*5CT341C, A803G17 (2.2)17 (2.1)9 (3.0)
NAT2*5DT341C
NAT2*5ET341C, G590A1 (0.34)
NAT2*5FT341C, C481T, C759T, A803G
NAT2*6AC282T, G590A206 (26.6)251 (30.3)66 (22.1)
NAT2*6BG590A1 (0.12)1 (0.34)
NAT2*6CC282T, G590A, A803G
NAT2*6DT111C, C282T, G590A
NAT2*7AG857A
NAT2*7BC282T, G857A15 (1.9)19 (2.3)8 (2.7)
NAT2*10G499ANDNDND
NAT2*11C481T
NAT2*12AA803G3 (0.4)4 (0.48)6 (2.0)
NAT2*12BC282T, A803G4 (1.3)
NAT2*12CC481T, A803G2 (0.67)
NAT2*13C282T7 (0.9)1 (0.12)14 (4.7)
NAT2*14AG191A3 (1.0)
NAT2*14BG191A, C282T1 (0.1)11 (3.7)
NAT2*14CG191A, T341C, C481T, A803G
NAT2*14DG191A, C282T, G590A
NAT2*14EG191A, A803G
NAT2*14FG191A, T341C, A803G
NAT2*14GG191A, C282T, A803G
NAT2*17A434C
NAT2*18A845C
NAT2*19C190TNDNDND
  • NOTE: Alleles were assigned using a PCR-based assay that detects 11 SNPs and can therefore distinguish among 26 NAT2 allele variants. Alleles in boldface are high-activity (rapid) alleles, whereas all others are low-activity (slow) alleles. “Intermediate” acetylator phenotype is assigned when an individual possesses one “slow” and one “rapid” allele. It should be noted that NAT2*10 phenotype is unknown. ND, Our assay does not detect the G499A or C190T SNPs and thus cannot distinguish these alleles.